MTH1 inhibition | MTH1 inhibitor review

Catalog No.	Product Name	Information	Product Use Citations
S7505	(S)-crizotinib	(S)-crizotinib, the (S)-enantiomer of crizotinib, is a potent MTH1 (NUDT1) inhibitor with IC50 of 72 nM in a cell-free assay.	Am J Respir Crit Care Med, 2020, 10.1164/rccm.202003-0627OC Sci Adv, 2020, 22;6(21):eaaz8521 Cancers (Basel), 2020, 27;12(5)pii: E1087
S7631	TH287	TH287 is a potent and selective MTH1 (NUDT1) inhibitor with IC50 of 0.8 nM.	Oncogene, 2021, 10.1038/s41388-021-02105-9 Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0507 Cancer Biother Radiopharm, 2020, 10.1089/cbr.2019.3031
S7632	TH588	TH588 is a potent and selective MTH1 (NUDT1) inhibitor with IC50 of 5 nM. It has no relevant inhibition of any of the other tested proteins at 100 μM, although TH588 showed reasonable selectivity when tested on a much larger panel of 87 enzymes, GPCRs, kinases, ion channels and transporters at 10 μM.	Cell Syst, 2019, 9(1):74-92.e8 Oncol Lett, 2018, 15(3):3240-3244 Oncol Lett, 2017, 13(4):2161-2168
S7505	(S)-crizotinib	(S)-crizotinib, the (S)-enantiomer of crizotinib, is a potent MTH1 (NUDT1) inhibitor with IC50 of 72 nM in a cell-free assay.	Am J Respir Crit Care Med, 2020, 10.1164/rccm.202003-0627OC Sci Adv, 2020, 22;6(21):eaaz8521 Cancers (Basel), 2020, 27;12(5)pii: E1087
S7631	TH287	TH287 is a potent and selective MTH1 (NUDT1) inhibitor with IC50 of 0.8 nM.	Oncogene, 2021, 10.1038/s41388-021-02105-9 Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0507 Cancer Biother Radiopharm, 2020, 10.1089/cbr.2019.3031
S7632	TH588	TH588 is a potent and selective MTH1 (NUDT1) inhibitor with IC50 of 5 nM. It has no relevant inhibition of any of the other tested proteins at 100 μM, although TH588 showed reasonable selectivity when tested on a much larger panel of 87 enzymes, GPCRs, kinases, ion channels and transporters at 10 μM.	Cell Syst, 2019, 9(1):74-92.e8 Oncol Lett, 2018, 15(3):3240-3244 Oncol Lett, 2017, 13(4):2161-2168

MTH1

MTH1 Products